Skip to content
Screener

Neuropace, Inc. NPCE Interest Income

Interest Income at other companies

LivaNova logo
LivaNovaLIVN
$3.83M-8.4%
ClearPoint Neuro logo
ClearPoint NeuroCLPT
$351K+132%
Inspire Medical Systems logo
Inspire Medical SystemsINSP
$3.74M-26.2%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
$4.19M+51.6%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$12.15M+68.7%

Other financials

Income statement

See full
Revenue$22.8M+17.1%
Gross profit$18.9M+16.6%
Operating income-$5.1M+37.2%
Net income-$6.2M+28.3%
EPS (diluted)-$0.18+30.8%

Balance sheet

See full
Cash & equivalents$12.8M-44.4%
Total debt$69.9M-2.2%
Total equity$11.9M-38.9%
Total assets$97.0M-8.6%

Cash flow

See full
Operating cash flow-$3.9M-87.1%
CapEx$125.0K-25.6%
Free cash flow-$4.0M-78.7%

Valuation

See full
Market cap$507.31M+74.0%
Enterprise value$564.47M+66.0%
P/S5.1×+1.7×

Profitability

See full
Gross margin79.6%+2.6pp
Operating margin-15.3%-4.3pp
Net margin-19.3%-5.2pp
FCF margin-12.2%-3.3pp

Returns & leverage

See full
Return on equity-122.1%-28.9pp
Debt / equity5.9×+2.2×
Current ratio4.9×-0.5×

Where this comes from

Reported directly by Neuropace, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:33 PM EDT
Fiscal quarter
Q4 FY2030
Calendar quarter
Q4 2030
Accession
0001528287-26-000030
(in thousands, except for share and per share amounts)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
General and administrative5,0276,0689,87110,114
Total operating expenses24,04924,40247,66546,293
Loss from continuing operations(5,143)(8,189)(10,748)(14,949)
Interest income5237181,0881,511
Interest expense(1,539)(2,059)(3,060)(4,212)
Other income (expense), net(41)(486)(206)(568)
Net loss and comprehensive loss from continuing operations(6,200)(10,016)(12,926)(18,218)
Net income from discontinued operations1,365372,978

Item 1. Financial Statements (Unaudited)

FAQ

What is Neuropace, Inc.'s interest income?
Neuropace, Inc. (NPCE) reported interest income of $523K in Q2 2026.
How has Neuropace, Inc.'s interest income changed year-over-year?
Neuropace, Inc.'s interest income decreased by 27.2% year-over-year, from $718K to $523K.
What is the long-term trend for Neuropace, Inc.'s interest income?
Over 4 years (2021 to 2025), Neuropace, Inc.'s interest income has grown at a 58.3% compound annual growth rate (CAGR), from $448K to $2.82M.
What does interest income mean?
Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.

Ask your AI about Neuropace, Inc.'s interest income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude